曲妥珠单抗联合辅助化疗治疗晚期乳腺癌的临床观察

曲妥珠单抗联合辅助化疗治疗晚期乳腺癌的临床观察
孙宏治;王巍;李晴;李强;杨涛;李东升
【期刊名称】《中国生化药物杂志》
【年(卷),期】2011(032)005
【摘要】Purpose To study the efficacy and adverse reactions of trastuzumab plus adjuvant chemotherapy for advanced breast cancer. Methods 120 cases of modified radical mastectomy for breast cancer patients,with advanced carcinoma diagnosed pathelogically,randomly divided into two groups,60 patients received conventional chemotherapy for the control group,60 patients received trastuzumab combined adjuvant chemotherapy treatment experimental group patients were compared in survival, recurrence rate, metastasis rate and adverse reactions. Results In the control group,the recurrence rate was 13. 3% and the transfer rate of 11.7% . In the experimental group,the recurrence rate was 1.7% ,with no distant metastasis and all survived. The main side effects of cardiac toxicity,gastrointestinal tract,skin rashes,joint and muscle
pain,leukopenia,etc. Can be tolerated. Conclusion Trastuzumab combined adjuvant chemotherapy is the treatment of advanced breast cancer patients with a safe and effective way to significantly reduce breast cancer recurrence rate and metastasis rate.%目的观察曲妥珠单杭联合辅助化疗治疗晚期乳腺癌的临床疗效及不良反应.方法选择120例改良根治术的乳腺癌患者,病理诊断均为晚期癌,随机分两组:60例接受常规化疗患者为对照组,60例接受曲妥珠
单抗联合辅助化疗治疗的患者为实验组.比较两组的生存率、复发率、转移率和不良反应.结果对照组局部复发率为13.3%,远处转移率11.7%,其中1例死亡.实验组局部复发率为1.7%,无远处转移,全部生存.两组复发率、转移率之间的差异均有统计学意义(P<0.05),而生存率无明显差异(P>0.05).两组不良反应发生率无明显差异.结论曲妥珠单抗联合辅助化疗是目前治疗晚期乳腺癌患者的一种安全有效的方法,能明显减少乳腺癌术后的复发率和转移率.
【总页数】3页(P398-400)
【作者】孙宏治;王巍;李晴;李强;杨涛;李东升
【作者单位】辽宁医学院附属第一医院,普外科,辽宁,锦州,121001;辽宁医学院附属第一医院,普外科,辽宁,锦州,121001;辽宁医学院附属第三医院肾内科,辽宁,锦州,121001;辽宁医学院附属第一医院,普外科,辽宁,锦州,121001;辽宁医学院附属第一医院,普外科,辽宁,锦州,121001;辽宁医学院附属第一医院,普外科,辽宁,锦
州,121001
【正文语种】中文
【中图分类】R979.1
【相关文献】
1.曲妥珠单抗联合化疗治疗晚期乳腺癌的观察与护理 [J], 廖瑞梅;柯娜;黄肖梅
2.曲妥珠单抗联合新辅助化疗治疗乳腺癌的疗效临床观察 [J], 全成海
3.曲妥珠单抗联合放化疗治疗HER-2阳性晚期乳腺癌的临床疗效以及疾病预后分析 [J], 谭明;向东华
4.曲妥珠单抗联合紫杉醇化疗治疗晚期乳腺癌的疗效及安全性分析 [J], 苏文
5.曲妥珠单抗联合CAF化疗治疗晚期乳腺癌临床效果观察 [J], 肖聪;张懿敏;孙圣荣
因版权原因，仅展示原文概要，查看原文内容请购买。